Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. aglyc

AGLYC

The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 AGLYC project word cloud

Explore the words cloud of the AGLYC project. It provides you a very rough idea of what is the project "AGLYC" about.

accounting    demonstrates    diagnosis    biomarker    model    small    sublicense    cardiovascular    97    min    2016    blood    vitro    device    almost    trl6    progression    commercialization    co    2023    women    onset    diseases    completion    19m    plasma    causing    reversible    84    quantification    glyc    diagnostics    smei    effectiveness    36m    death    detect    morbidity    rapid    stratification    ivd    cardiac    ischemia    sensitivity    don    prognosis    oxygen    jobs    patients    31    detects    6    2024    deaths    either    accounted    poc    tissue    61    647m    shortage    useless    risk    hrs    usa5eu    aglyc    man    levels    restriction    70m    globe    detecting    ebitda    medtech    90    prevent    tissues    damage    competitive    stage    medical    business    ischemic    apo    fact    estimate    diagnostic    cagr    right    detection    biomarkers    point    circulating    company    advantages    successful    103m    market    markers    organ    obviously    heart    irreversible    necrosis    care    global    glycardial    lab    39    2017    gt    sublicensed    cvd    2015    supply    pharmaceutical   

Project "AGLYC" data sheet

The following table provides information about the project.

Coordinator		 GLYCARDIAL DIAGNOSTICS, SL 

Organization address
address: CALLE BALDIRI REIXAC 48 - PLANTA 1 PUERTA B04 PARC CIENTIFIC DE BARCELONA TORRE R
city: BARCELONA
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.glycardial.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCARDIAL DIAGNOSTICS, SL ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

Cardiovascular diseases (CVD) are the leading cause of death/morbidity across the globe, accounting for 31% of all deaths in 2015. Early detection of ischemia (restriction in blood supply to tissues, causing oxygen shortage) is essential to prevent the progression of heart damage, but right now, we don’t have any biomarkers for the early detection of cardiac ischemia. In fact, almost 90% of the available in vitro diagnostic (IVD) methods are based on the quantification of markers of necrosis, an advanced stage of organ damage. Obviously, these methods are useless for the early detection of ischemic damage.

AGLYC is an IVD device based on the rapid quantification circulating plasma Apo J-Glyc levels as a novel biomarker for the diagnosis, prognosis and risk stratification of ischemia and ischemic tissue damage. AGLYC demonstrates a 97% sensitivity in detecting the presence of cardiac ischemia; market state of the art is 39%. It also detects ischemic damage at an early and reversible phase (30 min after ischemia onset); state of the art can only detect ischemia 6 hrs after its onset when tissue damage is irreversible. We are currently at TRL6 having the competitive advantages of high sensitivity, early detection and cost effectiveness.

The Global IVD market accounted for $61,103M in 2016 and is estimated to reach $84,647M by 2023, growing at a CAGR of 4.6% from 2017-2023. We have estimated a lab-based target market of >70M patients (USA5EU) and a Point of Care (POC) target market of >36M patients (USA5EU). Our main business model will be a sublicense model: a lab-based test will be developed and sublicensed to either a medical device company (like MedTech) or to a pharmaceutical company for the co-development and commercialization of the POC device. GlyCardial Diagnostics, S.L. is a small company of 4 (3 women, 1 man) but with the successful completion of the SMEI Phase 1 and 2 we estimate an EBITDA of around €19M, creating 10 new jobs by 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AGLYC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AGLYC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PRIVATETRACK (2019)

PRIVATETRACK: Privacy-friendly, low-power intelligent room occupancy detection and people counting.

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

COUNTMITMENT (2019)

NATURAL CAPITAL ACCOUNTANCY TO IMPROVE REPORTING AND ENVIRONMENTAL PERFORMANCE

Read More